To include your compound in the COVID-19 Resource Center, submit it here.

BioLineRx, Ramius, Royalty Pharma deal

BioLineRx will reacquire exclusive rights in North America to schizophrenia candidate CYP-1020 ( BL-1020) from Cypress

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE